As noted in the introduction, recent data also link functional RB1 to responsiveness to pharmacological CDK4/6 inhibition, adding interest to our findings and raising the possibility that pT356RB1 may have utility in stratifying SCCHN patients for clinical trials of CDK4/6 inhibition. This evidence concerns the gene CDK4 and head and neck squamous cell carcinoma.